Incidence determinants and serological correlates of reactive symptoms following SARS-CoV-2 vaccination

Hayley Holt^{1

2

3}, David A Jolliffe^{4

5}, Mohammad Talaei⁴, Sian Faustini⁶, Giulia Vivaldi^{4

7}, Matthew Greenig⁴, Alex G Richter⁶, Ronan A Lyons⁸, Christopher J Griffiths^{4

5}, Frank Kee⁹, Aziz Sheikh¹⁰, Gwyneth A Davies⁸, Seif O Shaheen⁴, Adrian R Martineau^{4

7

5}

Affiliations

¹ Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. h.holt@qmul.ac.uk.
² Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. h.holt@qmul.ac.uk.
³ Asthma UK Centre for Applied Research, Queen Mary University of London, London, UK. h.holt@qmul.ac.uk.
⁴ Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
⁵ Asthma UK Centre for Applied Research, Queen Mary University of London, London, UK.
⁶ Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
⁷ Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
⁸ Population Data Science, Swansea University Medical School, Singleton Park, Swansea, UK.
⁹ Centre for Public Health Research (NI), Queen's University Belfast, Belfast, UK.
¹⁰ Usher Institute, University of Edinburgh, Edinburgh, UK.

PMID: 36841835
PMCID: PMC9959934
DOI: 10.1038/s41541-023-00614-0

Incidence determinants and serological correlates of reactive symptoms following SARS-CoV-2 vaccination

Hayley Holt et al. NPJ Vaccines. 2023.

. 2023 Feb 25;8(1):26.

doi: 10.1038/s41541-023-00614-0.

Authors

Affiliations

¹ Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. h.holt@qmul.ac.uk.
² Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. h.holt@qmul.ac.uk.
³ Asthma UK Centre for Applied Research, Queen Mary University of London, London, UK. h.holt@qmul.ac.uk.
⁴ Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
⁵ Asthma UK Centre for Applied Research, Queen Mary University of London, London, UK.
⁶ Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
⁷ Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
⁸ Population Data Science, Swansea University Medical School, Singleton Park, Swansea, UK.
⁹ Centre for Public Health Research (NI), Queen's University Belfast, Belfast, UK.
¹⁰ Usher Institute, University of Edinburgh, Edinburgh, UK.

PMID: 36841835
PMCID: PMC9959934
DOI: 10.1038/s41541-023-00614-0

Abstract

Prospective population-based studies investigating associations between reactive symptoms following SARS-CoV-2 vaccination and serologic responses to vaccination are lacking. We therefore conducted a study in 9003 adults from the UK general population receiving SARS-CoV-2 vaccines as part of the national vaccination programme. Titres of combined IgG/IgA/IgM responses to SARS-CoV-2 spike (S) glycoprotein were determined in eluates of dried blood spots collected from all participants before and after vaccination. 4262 (47.3%) participants experienced systemic reactive symptoms after a first vaccine dose. Factors associating with lower risk of such symptoms included older age (aOR per additional 10 years of age 0.85, 95% CI: 0.81-0.90), male vs. female sex (0.59, 0.53-0.65) and receipt of an mRNA vaccine vs. ChAdOx1 nCoV-19 (0.29, 0.26-0.32 for BNT162b2; 0.06, 0.01-0.26 for mRNA-1273). Higher risk of such symptoms was associated with SARS-CoV-2 seropositivity and COVID-19 symptoms prior to vaccination (2.23, 1.78-2.81), but not with SARS-CoV-2 seropositivity in the absence of COVID-19 symptoms (0.94, 0.81-1.09). Presence vs. absence of self-reported anxiety or depression at enrolment associated with higher risk of such symptoms (1.24, 1.12-1.39). Post-vaccination anti-S titres were higher among participants who experienced reactive symptoms after vaccination vs. those who did not (P < 0.001). We conclude that factors influencing risk of systemic symptoms after SARS-CoV-2 vaccination include demographic characteristics, pre-vaccination SARS-CoV-2 serostatus and vaccine type. Participants experiencing reactive symptoms following SARS-CoV-2 vaccination had higher post-vaccination titres of IgG/A/M anti-S antibodies. Improved public understanding of the frequency of reactogenic symptoms and their positive association with vaccine immunogenicity could potentially increase vaccine uptake.

PubMed Disclaimer

Conflict of interest statement

J.S. declares receipt of payments from Reach plc for news stories written about recruitment to, and findings of, the COVIDENCE UK study. A.S. is a member of the Scottish Government Chief Medical Officer’s COVID-19 Advisory Group and its Standing Committee on Pandemics. He is also a member of the UK Government’s NERVTAG’s Risk Stratification Subgroup. ARM declares receipt of funding in the last 36 months to support vitamin D research from the following companies who manufacture or sell vitamin D supplements: Pharma Nord Ltd, DSM Nutritional Products Ltd, Thornton & Ross Ltd and Hyphens Pharma Ltd. ARM also declares support for attending meetings from the following companies who manufacture or sell vitamin D supplements: Pharma Nord Ltd and Abiogen Pharma Ltd. ARM also declares participation on the Data and Safety Monitoring Board for the Chair, DSMB, VITALITY trial (Vitamin D for Adolescents with HIV to reduce musculoskeletal morbidity and immunopathology). ARM also declares unpaid work as a Programme Committee member for the Vitamin D Workshop. ARM also declares receipt of vitamin D capsules for clinical trial use from Pharma Nord Ltd, Synergy Biologics Ltd and Cytoplan Ltd. All other authors declare have no competing interests.

Figures

**Fig. 1. Proportions of participants experiencing systemic or local reactive symptoms after receiving first and second doses of ChAdOx1, BNT162b2, and mRNA-1273 vaccines.**
Panel a shows systemic symptoms are more common with ChAdOx1 vaccine following first dose. Panel b shows local symptoms are more common with BNT162b2 vaccine following second dose.

See this image and copyright information in PMC

References

1. Johns Hopkins Coronavirus Resource Center. Coronavirus Resource Center. Available at https://coronavirus.jhu.edu2022.
1. Sallam M. COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates. Vaccines. 2021;9:160. doi: 10.3390/vaccines9020160. - DOI - PMC - PubMed
1. Herve C, Laupeze B, Del Giudice G, Didierlaurent AM, Tavares Da Silva F. The how’s and what’s of vaccine reactogenicity. NPJ Vaccines. 2019;4:39. doi: 10.1038/s41541-019-0132-6. - DOI - PMC - PubMed
1. Rief W. Fear of adverse effects and COVID-19 vaccine hesitancy: recommendations of the treatment expectation expert group. JAMA Health Forum. 2021;2:e210804. doi: 10.1001/jamahealthforum.2021.0804. - DOI - PubMed
1. Chapin-Bardales J, Gee J, Myers T. Reactogenicity following receipt of mRNA-Based COVID-19 Vaccines. J. Am. Med. Assoc. 2021;325:2201–2202. doi: 10.1001/jama.2021.5374. - DOI - PubMed

LinkOut - more resources

Full Text Sources
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Incidence determinants and serological correlates of reactive symptoms following SARS-CoV-2 vaccination

Affiliations

Incidence determinants and serological correlates of reactive symptoms following SARS-CoV-2 vaccination

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

LinkOut - more resources

Full Text Sources